You are here
AURITEC PHARMACEUTICALS, INC.
UEI: QX8KP6JKQ2L8
# of Employees: 6
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
IND-enabling Preclinical Development of a Sustained-release Pritelivir Intravaginal ring for the Treatment and Prophylaxis of Genital Herpes
Amount: $1,025,000.00SUMMARY The broad, long-term goal of this project is to develop a pritelivir intravaginal ring (IVR) for the treatment and pre-exposure prophylaxis of genital herpes, a common problem that affects mor ...
SBIRPhase II2023Department of Health and Human Services National Institutes of Health -
Long-acting injectable tacrolimus for chronic immunosuppression
Amount: $2,047,614.00PROJECT SUMMARY The broad, long-term goal of this Direct to Phase II SBIR is to improve immunosuppression outcomes in organ transplant recipients by developing a long-acting injectable calcineurin inh ...
SBIRPhase II2022Department of Health and Human Services National Institutes of Health -
Longer-acting intravaginal formulation of buprenorphine
Amount: $1,690,670.00PROJECT SUMMARY The broad, long-term goal of this research program is to empower women suffering from opioid use disorder (OUD) through the development of a long-acting intravaginal ring (IVR) formula ...
SBIRPhase II2021Department of Health and Human Services National Institutes of Health -
I-Corps: Longer-acting intravaginal formulation of buprenorphine
Amount: $308,608.00PROJECT SUMMARY The broad, long-term goal of this research program is to empower women suffering from opioid use disorder (OUD) through the development of a long-acting intravaginal ring (IVR) formula ...
SBIRPhase I2020Department of Health and Human Services National Institutes of Health -
IND-enabling preclinical development of a sustained-release Pritelivir intravaginal ring for the treatment and prophylaxis of Genital Herpes in women
Amount: $1,860,561.00SUMMARY (changes are underlined) The broad, long-term goal of this project is to develop a pritelivir intravaginal ring (IVR) for the treatment and pre-exposure prophylaxis of genital herpes, a common ...
SBIRPhase II2019Department of Health and Human Services National Institutes of Health -
IND-enabling preclinical development of a system for the multipurpose prevention of HIV and unintended pregnancy
Amount: $1,999,996.00SUMMARY (changes are underlined) The broad, long-term goal of this research program is to develop an intravaginal multipurpose prevention technology (MPT) product to provide HIV pre-exposure prophylax ...
SBIRPhase II2019Department of Health and Human Services National Institutes of Health -
Preclinical development of an intravaginal ring for the sustained release of Pritelivir for the treatment and prophylaxis of Genital Herpes in women
Amount: $224,484.00SUMMARY The broadlong term goal of this project is to develop a pritelivir intravaginal ringIVRfor the treatment and pre exposure prophylaxis of genital herpesa common problem that affects more thanmi ...
SBIRPhase I2018Department of Health and Human Services National Institutes of Health -
Preclinical development of an intravaginal ring for the sustained release of octreotide for the treatment of acromegaly
Amount: $224,881.00PROJECT SUMMARY The broad long term goal of this research program is to develop a novel treatment for women with acromegaly a sustained release intravaginal ring IVR formulation for octreotide In ...
SBIRPhase I2017Department of Health and Human Services National Institutes of Health -
Preclinical development of a multipurpose intravaginal ring for the prevention of HIV and unintended pregnancy
Amount: $219,324.00DESCRIPTION provided by applicant The broad long term goal of this research program is to develop a dual protection intravaginal product that will provide contraception and pre exposure HIV prophy ...
SBIRPhase I2016Department of Health and Human Services National Institutes of Health -
Clinical Safety and Pharmacokinetics of Sustained Release Depot Tacrolimus
Amount: $1,299,084.00PROJECT SUMMARY The long term goal of this research is to reduce toxicity and graft rejection due to dosing problems with the calcineurin inhibitors by developing a sustained release subcutaneous inj ...
SBIRPhase II2016Department of Health and Human Services National Institutes of Health